| Aromatase Inhibitor studied in …STUDIED_INderived36 of 36show fewer |
|---|
| → studied in | NCT07222267Phase 1 · recruiting An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors · 36 trials list this drug (13 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05384119Phase 1 · terminated Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06440967Phase 3 · active not recruiting A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy · 36 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07796880Phase 2 · recruiting Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer · 36 trials list this drug (13 active) | — | — | Breast Neoplasm,Early Stage Breast Carcinoma,HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07782840Phase 2 · not yet recruiting QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03959891Phase 1 · active not recruiting AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06218303Phase 1 · recruiting Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ · 36 trials list this drug (13 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05043506completed European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04188548Phase 1 · active not recruiting A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07618923Phase 2 · not yet recruiting Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer · 36 trials list this drug (13 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07400523Phase 3 · recruiting Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07527806Phase 2 · not yet recruiting Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05700006completed Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging · 36 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02767661Phase 3 · completed Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04762979Phase 2 · active not recruiting Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer · 36 trials list this drug (13 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06107673Phase 2 · recruiting Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06495164active not recruiting A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06086340completed Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself. · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02040857Phase 2 · completed Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01160211Phase 3 · completed A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer · 36 trials list this drug (13 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05012644completed Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05361655completed Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03477396Phase 2 · completed Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer · 36 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05801705unknown Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study · 36 trials list this drug (13 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00773695Phase 2 · completed A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01220128Phase 2 · terminated Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer · 36 trials list this drug (13 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01491737Phase 2 · completed A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03846583Phase 1 · withdrawn Tucatinib + Abemaciclib + Herceptin for HER2+ MBC · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01446159Phase 2 · completed Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer · 36 trials list this drug (13 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03910712Phase 2 · unknown Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02910050Phase 2 · unknown Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01654185Phase 2 · completed Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01814865Phase 2 · withdrawn Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer · 36 trials list this drug (13 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00766532Phase 4 · completed Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00935558Phase 2 · withdrawn Dendritic Cell Based Therapy for Breast Cancer Patients · 36 trials list this drug (13 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00973505unknown CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI) · 36 trials list this drug (13 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |